Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Advances in Anatomic Pathology

Volumn 24, Issue 6, 2017, Pages 311-335

  Hendry, Shona ^a,c   Salgado, Roberto ^ai,ap   Gevaert, Thomas ^ak,am   Russell, Prudence A ^d,g   John, Tom ^h,i,j   Thapa, Bibhusal ^e,i   Christie, Michael ^f   Van De Vijver, Koen ^p   Estrada, M V ^cc   Gonzalez Ericsson, Paula I ^bh   Sanders, Melinda ^a   Solomon, Benjamin ^b   Solinas, Cinzia ^ao   Van Den Eynden, Gert G G M ^aj,ao   Allory, Yves ^q,r,s   Preusser, Matthias ^y   Hainfellner, Johannes ^z   Pruneri, Giancarlo ^ab,ac   Vingiani, Andrea ^ab,ac   Demaria, Sandra ^bz   Symmans, Fraser ^ca   Nuciforo, Paolo ^ag   Comerma, Laura ^ag   Thompson, E A ^bs   Lakhani, Sunil ^k,l   Kim, Seong Rim ^bg   Schnitt, Stuart ^bn,bo   Colpaert, Cecile ^an   Sotiriou, Christos ^ap   Scherer, Stefan J ^cg   Ignatiadis, Michail ^ap   Badve, Sunil ^bt   Pierce, Robert H ^bu   Viale, Giuseppe ^ad   Sirtaine, Nicolas ^ap   Penault Llorca, Frederique ^w,x   Sugie, Tomohagu ^ar   Fineberg, Susan ^bk,bl   Paik, Soonmyung ^as,bg   Srinivasan, Ashok ^bg   Richardson, Andrea ^a,bm,bo   Wang, Yihong ^be,bf   Chmielik, Ewa ^at,au   Brock, Jane ^bm,bo   Johnson, Douglas B ^bh,bi   Balko, Justin ^bh,bi   Wienert, Stephan ^aw,ax   Bossuyt, Veerle ^bj   Michiels, Stefan ^t   Ternes, Nils ^t   Burchardi, Nicole ^ay   Luen, Stephen J ^b,c   Savas, Peter ^b,c   Klauschen, Frederick ^aw   Watson, Peter H ^d,az   Nelson, Brad H ^d,az,ba   Criscitiello, Carmen ^ab   O'Toole, Sandra ^m,n   Larsimont, Denis ^ap   De Wind, Roland ^ap   Curigliano, Giuseppe ^ab   André, Fabrice ^u,v   Lacroix Triki, Magali ^u   Van De Vijver, Mark ^p   Rojo, Federico ^ah   Floris, Giuseppe ^al   Bedri, Shahinaz ^bd   Sparano, Joseph ^bk   Rimm, David ^bj   Nielsen, Torsten ^bb   Kos, Zuzana ^bc   Hewitt, Stephen ^ce   Singh, Baljit ^bv   Farshid, Gelareh ^d,o   Loibl, Sibylle ^ay   Allison, Kimberly H ^cb   Tung, Nadine ^bp   Adams, Sylvia ^bv,bw   Willard Gallo, Karen ^ao   Horlings, Hugo M ^d   Gandhi, Leena ^bq,bv   Moreira, Andre ^bx   Hirsch, Fred ^br   Dieci, Maria V ^ae,af   Urbanowicz, Maria ^aq   Brcic, Iva ^aa   Korski, Konstanty ^av   Gaire, Fabien ^av   Koeppen, Hartmut ^cd   Lo, Amy ^cb,cd   Giltnane, Jennifer ^cd   Rebelatto, Marlon C ^cf   Steele, Keith E ^cf   Zha, Jiping ^cf   Emancipator, Kenneth ^ch   Juco, Jonathan W ^ch   Denkert, Carsten ^aw   Reis Filho, Jorge ^by   Loi, Sherene ^b   Fox, Stephen B ^a,c   more..

^a Department of Pathology ^*  (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c Molecular Imaging and Therapeutic Nuclear Medicine at Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology at University of Melbourne   (Australia)

^d UNIVERSITY OF VICTORIA   (Canada)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h AUSTIN HEALTH   (Australia)

ⁱ OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^j LA TROBE UNIVERSITY   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^m GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

ⁿ Department of Anatomical Pathology   (Australia)

^o UNIVERSITY OF ADELAIDE   (Australia)

^p NETHERLANDS CANCER INSTITUTE   (Netherlands)

^q UNIVERSITÉ PARIS EST   (France)

^r INSERM   (France)

^s HENRI MONDOR HOSPITAL   (France)

^t CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^u Universite Paris Sud   (France)

^v UNIVERSITÉ PARIS SACLAY   (France)

^w Jean Perrin Comprehensive Cancer Centre   (Canada)

^x UNIVERSITÉ CLERMONT AUVERGNE   (France)

^y Department of Medicine   (France)

^z MEDICAL UNIVERSITY OF VIENNA   (Austria)

^aa MEDICAL UNIVERSITY OF GRAZ   (Austria)

^ab EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ac School of Medicine   (Austria)

^ad UNIVERSITY OF MILAN   (Italy)

^ae UNIVERSITY OF PADOVA   (Italy)

^af VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^ag VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^ah UAM)   (Spain)

^ai Department of Pathology   (Senegal)

^aj ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^ak SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^al UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^am Algemeen Ziekenhuis Klina   (Belgium)

^an SINT AUGUSTINUS HOSPITAL   (Belgium)

^ao Molecular Immunology Unit   (Belgium)

^ap JULES BORDET INSTITUTE   (Belgium)

^aq EORTC DATA CENTER   (Belgium)

^ar KANSAI MEDICAL UNIVERSITY   (Japan)

^as Yonsei University College of Medicine   (South Korea)

^at INSTITUTE OF ONCOLOGY   (Poland)

^au INSTITUTE OF ONCOLOGY   (Poland)

^av ROCHE DIAGNOSTICS GMBH   (Germany)

^aw CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^ax VMSCOPE GMBH   (Germany)

^ay German Breast Group   (Germany)

^az BRITISH COLUMBIA CANCER AGENCY   (Canada)

^ba Departments of Medical Genetics   (Australia)

^bb UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^bc UNIVERSITY OF OTTAWA   (Canada)

^bd WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^be RHODE ISLAND HOSPITAL   (United States)

^bf BROWN UNIVERSITY   (United States)

^bg NSABP Foundation Inc   (United States)

^bh VANDERBILT INGRAM CANCER CENTER   (United States)

^bi VANDERBILT UNIVERSITY   (United States)

^bj YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bk ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^bl MONTEFIORE MEDICAL CENTER   (United States)

^bm BRIGHAM AND WOMEN S HOSPITAL   (United States)

^bn Beth Israel Deaconess Cancer Center   (United States)

^bo HARVARD MEDICAL SCHOOL   (United States)

^bp BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^bq DANA FARBER CANCER INSTITUTE   (United States)

^br UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^bs MAYO CLINIC   (United States)

^bt INDIANA UNIVERSITY   (United States)

^bu USA   (United States)

^bv NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^bw NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bx NEW YORK UNIVERSITY   (United States)

^by MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bz WEILL CORNELL MEDICAL COLLEGE   (United States)

^ca UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^cb STANFORD UNIVERSITY   (United States)

^cc UNIVERSITY OF CALIFORNIA   (United States)

^cd GENENTECH INC   (United States)

^ce NATIONAL CANCER INSTITUTE   (United States)

^cf Translational Sciences   (United States)

^cg NOVARTIS PHARMA AG   (Switzerland)

^ch MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

biomarkers; cancer; immunotherapy; lymphocytes; pathology; tumor infiltrating

Indexed keywords

TUMOR MARKER;

BRAIN TUMOR; COLORECTAL CARCINOMA; ENDOMETRIUM CARCINOMA; GASTROINTESTINAL CARCINOMA; GLIOMA; HEAD AND NECK CARCINOMA; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MELANOMA; MENINGIOMA; MESOTHELIOMA; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; RENAL CELL CARCINOMA; REVIEW; SOLID MALIGNANT NEOPLASM; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; UROGENITAL TRACT CARCINOMA; BIOPSY; ENDOMETRIUM TUMOR; FEMALE; GASTROINTESTINAL TUMOR; HEAD AND NECK TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG TUMOR; OVARY TUMOR; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; SKIN TUMOR; STANDARDS; UROGENITAL TRACT TUMOR;

BIOMARKERS, TUMOR; BIOPSY; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENDOMETRIAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MESOTHELIOMA; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 85032022216     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000161     Document Type: Review

References (331)

1. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-271.
2. Denkert C, Wienert S, Poterie A, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016;29: 1155-1164.
3. McGovern VJ, Mihm MC Jr, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32:1446-1457.
4. Elder DE, DuPont G, Van Horn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer. 1985;56: 413-418.
5. Clark WH Jr, Elder DE, DuPont G, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
6. Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5): v126-v132.
7. Busam KJ, Antonescu CR, Marghoob AA, et al. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: a study of interobserver agreement. Am J Clin Pathol. 2001;115:856-860.
8. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77: 1303-1310.
9. Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31:4252-4259.
10. Tuthill RJ, Unger JM, Liu PY, et al. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group Study evaluating nine factors and a test of the clark logistic regression prediction model. Am J Clin Pathol. 2002;118:504-511.
11. Weiss SA, Han SW, Lui K, et al. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Hum Pathol. 2016;57:116-125.
12. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678-2683.
13. Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427-432.
14. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869-875.
15. Mandala M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 2009;45:2537-2545.
16. Rao UN, Lee SJ, Luo W, et al. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010;133:646-653.
17. Eriksson H, Frohm-Nilsson M, Jaras J, et al. Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study. Br J Dermatol. 2015;172:175-186.
18. Hillen F, Baeten CI, van de Winkel A, et al. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother. 2008;57:97-106.
19. Martinez-Rodriguez M, Thompson AK, Monteagudo C. A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma. Histopathology. 2014;65:726-728.
20. van Houdt IS, Sluijter BJ, Moesbergen LM, et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer. 2008;123:609-615.
21. Miracco C, Mourmouras V, Biagioli M, et al. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep. 2007;18:1115-1122.
22. Vasaturo A, Di Blasio S, Verweij D, et al. Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. Histopathology. 2017;70:643-649.
23. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161:1215-1228.
24. Pasquali S, Spillane A. Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy. Cancer Treat Rev. 2014;40:893-899.
25. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
26. Duprat JP, Brechtbulh ER, Costa de Sa B, et al. Absence of tumor-infiltrating lymphocyte is a reproducible predictive factor for sentinel lymph node metastasis: a multicenter database study by the Brazilian Melanoma Group. PLoS One. 2016;11:e0148160.
27. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107:2436-2445.
28. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302-309.
29. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histo-pathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74:43-47.
30. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106:20429-20434.
31. Kakavand H, Vilain RE, Wilmott JS, et al. Tumor PD-L1 expression, immune cell correlates and PD-1 + lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol. 2015;28:1535-1544.
32. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681-1696.
33. Bremnes RM, Donnem T, Al-Saad S, et al. The role of tumor stroma in cancer progression and prognosis; emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6:209-217.
34. Ruiter D, Bogenrieder T, Elder D, et al. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol. 2002;3:35-43.
35. Ladanyi A, Somlai B, Gilde K, et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004;10:521-530.
36. Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459-1469.
37. Ladanyi A, Kiss J, Mohos A, et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immun-other. 2011;60:1729-1738.
38. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571.
39. Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2015;8: 327ra326.
40. MacCarty WC. Principles of prognosis in cancer. J Am Med Assoc. 1931;96:30-33.
41. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the "Immunoscore" in the classification of malignant tumours. J Pathol. 2014;232:199-209.
42. Nowak JA, Hornick JL. Molecular evaluation of colorectal adenocarcinoma: current practice and emerging concepts. Surg Pathol Clin. 2016;9:427-439.
43. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10:13-27.
44. Asad Umar C, Boland R, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268.
45. Alexander J, Watanabe T, Wu T, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527-535.
46. Greenson JK, Bonner JD, Ben-Yzhak O, et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol. 2003;27:563-570.
47. Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417-2422.
48. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastro-enterology. 2007;133:48-56.
49. Joost P, Bendahl P, Halvarsson B, et al. Efficient and reproducible identification of mismatch repair deficient colon cancer: validation of the MMR index and comparison with other predictive models. BMC Clin Pathol. 2013;13:33.
50. Halvarsson B, Anderson H, Domanska K, et al. Clinicopa-thologic factors identify sporadic mismatch repair-defective colon cancers. Am J Clin Pathol. 2008;129:238-244.
51. Roman R, Verdu M, Calvo M, et al. Microsatellite instability of the colorectal carcinoma can be predicted in the conventional pathologic examination. A prospective multicentric study and the statistical analysis of 615 cases consolidate our previously proposed logistic regression model. Virchows Arch. 2010;456:533-541.
52. Hyde A, Fontaine D, Stuckless S, et al. A histology-based model for predicting microsatellite instability in colorectal cancers. Am J Surg Pathol. 2010;34:1820-1829.
53. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: colorectal (Version 2.2016). 2016. Available at: www.nccn.org/professionals/physician-gls/pdf/genetics-colon.pdf. Accessed January 19, 2017.
54. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863-875.
55. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-618.
56. Guastadisegni C, Colafranceschi M, Ottini L, et al. Micro-satellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010;46:2788-2798.
57. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohis-tochemistry versus microsatellite instability testing in pheno-typing colorectal tumors. J Clin Oncol. 2002;20:1043-1048.
58. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33:1639-1645.
59. Glaire MA, Domingo E, Vermeulen L, et al. POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis. Ann Oncol. 2016;27:460O.
60. Rozek LS, Schmit SL, Greenson JK, et al. Tumor-infiltrating lymphocytes, Crohn's-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst. 2016;108:djw027.
61. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986;39:585-589.
62. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41: 2645-2654.
63. Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg. 2012;147:366-371.
64. Richards CH, Flegg KM, Roxburgh CS, et al. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer. 2012;106:2010-2015.
65. Richards CH, Roxburgh CS, Powell AG, et al. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer. 2014;50:309-319.
66. Vayrynen JP, Vornanen JO, Sajanti S, et al. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch. 2012;460:455-465.
67. Park JH, McMillan DC, Edwards J, et al. Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer. OncoImmunology. 2016;5:e1098801.
68. Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205.
69. Broussard EK, Disis ML. TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol. 2011; 29:601-603.
70. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666.
71. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
72. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944-5951.
73. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610-618.
74. Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698-711.
75. Galon J, Mlecnik B, Marliot F, et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1, 336 patients. J Clin Oncol. 2016;34(suppl):3500. Abstract.
76. Hermitte F. Biomarkers immune monitoring technology primer: Immunoscore(R) colon. J Immunother Cancer. 2016;4:57.
77. Mei Z, Liu Y, Liu C, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014;110:1595-1605.
78. Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891-1899.
79. Teng F, Mu D, Meng X, et al. Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. Am J Cancer Res. 2015; 5:2064-2074.
80. Teng F, Meng X, Kong L, et al. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Transl Res. 2015;166:721-732 e721.
81. Yasuda K, Nirei T, Sunami E, et al. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiation Oncology. 2011;6:49.
82. McCoy MJ, Hemmings C, Miller TJ, et al. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer. 2015;113:1677-1686.
83. Shinto E, Hase K, Hashiguchi Y, et al. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2014;21(suppl 3): S414-S421.
84. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics 2012. CA Cancer J Clin. 2015;65:87-108.
85. Kunk PR, Bauer TW, Slingluff CL, et al. From bench to bedside a comprehensive review of pancreatic cancer immu-notherapy. J Immunother Cancer. 2016;4:14.
86. El-Khoueiry AB, Sangro B, Yau TC, et al. Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study. J Clin Oncol. 2016;34:4012. Abstr.
87. Wang M, Busuttil RA, Pattison S, et al. Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol. 2016;22:6373-6384.
88. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System, 4th ed. Lyon: IARC; 2010.
89. Song HJ, Srivastava A, Lee J, et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology. 2010;139:84-92 e82.
90. Kang BW, Seo AN, Yoon S, et al. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. Ann Oncol. 2016;27:494-501.
91. Giampieri R, Maccaroni E, Mandolesi A, et al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer. 2017;20: 156-163.
92. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99:1704-1711.
93. Chiaravalli AM, Feltri M, Bertolini V, et al. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2005;448:344-353.
94. Hennequin A, Derangere V, Boidot R, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology. 2015;5:e1054598.
95. Li K, Zhu Z, Luo J, et al. Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer. Int J Clin Exp Pathol. 2015;8:14725-14732.
96. Haas M, Dimmler A, Hohenberger W, et al. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterology. 2009;9:65.
97. Kim K-J, Lee KS, Cho HJ, et al. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8 + cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol. 2014;45:285-293.
98. Liu K, Yang K, Wu B, et al. Tumor-infiltrating immune cells are associated with prognosis of gastric cancer. Medicine (Baltimore). 2015;94:e1631.
99. Zhou S, Xu S, Tao H, et al. CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One. 2013;8:e74430-e74437.
100. Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794-801.
101. Solinas C, Pusole G, Demurtas L, et al. Tumor infiltrating lymphocytes in gastrointestinal tumors: controversies and future clinical implications. Crit Rev Oncol Hematol. 2017;110:106-116.
102. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372: 2509-2520.
103. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-209.
104. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48-61.
105. Dai C, Geng R, Wang C, et al. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. 2016;10:1551-1558.
106. Kawazoe A, Kuwata T, Kuboki Y, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20:407-415.
107. Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9: 454-467.
108. Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: cancer-associated fibro-blasts, endothelial and inflammatory cells. World J Gastro-enterol. 2016;22:2678-2700.
109. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47-52.
110. Hiraoka N, Ino Y, Yamazaki-Itoh R, et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015;112:1782-1790.
111. Hart PA, Smyrk TC, Bamlet WR, et al. Impact of intra-tumoral inflammation on survival after pancreatic cancer resection. Pancreas. 2016;45:123-126.
112. Tang Y, Xu X, Guo S, et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarci-noma. PLoS One. 2014;9:e91551-e91559.
113. Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914-923.
114. Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26-e31.
115. Tewari N, Zaitoun AM, Arora A, et al. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC Cancer. 2013;13:436.
116. Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. 2016;122:367-377.
117. Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27:407-414.
118. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
119. Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4:419-430.
120. Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66:342-351.
121. Remark R, Becker C, Gomez JE, et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med. 2015;191:377-390.
122. Carbone DP, Gandara DR, Antonia SJ, et al. Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol. 2015;10:974-984.
123. Donnem T, Kilvaer TK, Andersen S, et al. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. 2016;27:225-232.
124. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
125. Brahmer JR, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
126. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 2016;387: 1837-1846.
127. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
128. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-265.
129. Geng Y, Shao Y, He W, et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem. 2015;37:1560-1571.
130. Horne ZD, Jack R, Gray ZT, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011;171:1-5.
131. Kilic A, Landreneau RJ, Luketich JD, et al. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. 2011;167:207-210.
132. Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107: dju435.
133. Zeng D, Yu Y, Ou Q, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget. 2016;7:13765-13781.
134. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14:5220-5227.
135. Ameratunga M, Asadi K, Lin X, et al. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. PLoS One. 2016;11:e0153954.
136. Al-Shibli K, Al-Saad S, Andersen S, et al. The prognostic value of intraepithelial and stromal CD3-, CD117-and CD138-positive cells in non-small cell lung carcinoma. APMIS. 2010;118:371-382.
137. Al-Shibli K, Al-Saad S, Donnem T, et al. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009;55:301-312.
138. Donnem T, Hald SM, Paulsen EE, et al. Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res. 2015;21:2635-2643.
139. Paulsen EE, Kilvaer T, Khanehkenari MR, et al. CD45RO(+) memory T lymphocytes-a candidate marker for TNM-Immunoscore in squamous non-small cell lung cancer. Neoplasia. 2015;17:839-848.
140. Pelletier MP, Edwardes MD, Michel RP, et al. Prognostic markers in resectable non-small cell lung cancer: a multi-variate analysis. Can J Surg. 2001;44:180-188.
141. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107: 2866-2872.
142. Ruffini E, Asioli S, Filosso PL, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009;87:365-371; discussion 371-372.
143. Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31:490-498.
144. Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7-14.
145. Alifano M, Mansuet-Lupo A, Lococo F, et al. Systemic inflammation, nutritional status and tumor immune micro-environment determine outcome of resected non-small cell lung cancer. PLoS One. 2014;9:e106914.
146. Carus A, Ladekarl M, Hager H, et al. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer. 2013;81:130-137.
147. Goc J, Germain C, Vo-Bourgais TK, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74:705-715.
148. Ilie M, Hofman V, Ortholan C, et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2012;118:1726-1737.
149. Kim MY, Koh J, Kim S, et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 2015;88:24-33.
150. Kinoshita T, Muramatsu R, Fujita T, et al. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann Oncol. 2016;27:2117-2123.
151. Djenidi F, Adam J, Goubar A, et al. CD8+CD103 + tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194:3475-3486.
152. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275-280.
153. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113:1387-1395.
154. Kayser G, Schulte-Uentrop L, Sienel W, et al. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas. Lung Cancer. 2012;76:445-451.
155. Liu H, Zhang T, Ye J, et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother. 2012;61:1849-1856.
156. Tao H, Mimura Y, Aoe K, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012;75:95-101.
157. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94:1003-1009.
158. Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol. 2016;34:1223-1230.
159. Feng W, Li Y, Shen L, et al. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer. Oncotarget. 2016;7:7227-7240.
160. Johnson SK, Kerr KM, Chapman AD, et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer. 2000;27:27-35.
161. Mignon S, Willard-Gallo K, Van Den Eynden G, et al. P3.02c-087 the relationship of TILs and PD-L1 expression in NSCLC adenocarcinoma in little to non-smokers with driver mutations and outcome parameters. J Thorac Oncol. 2017;12: S1331.
162. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26: 4410-4417.
163. Yamada N, Oizumi S, Kikuchi E, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59:1543-1549.
164. Anraku M, Cunningham KS, Yun Z, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008;135:823-829.
165. Salvesen HB, MacDonald N, Ryan P, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res. 2000;6:3607-3613.
166. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66:7810-7817.
167. Mills AM, Longacre TA. Lynch syndrome screening in the gynecologic tract: current state of the art. Am J Surg Pathol. 2016;40:e35-e44.
168. Shia J, Black D, Hummer AJ, et al. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008;39:116-125.
169. Garg K, Leitao MM, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33:925-933.
170. Ferguson SE, Aronson M, Pollett A, et al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer. 2014;120:3932-3939.
171. Rabban JT, Calkins SM, Karnezis AN, et al. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Am J Surg Pathol. 2014;38:793-800.
172. Ryan P, Mulligan AM, Aronson M, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endome-trial cancer encountered in the context of familial gastro-intestinal cancer registries. Cancer. 2012;118:681-688.
173. Mills AM, Liou S, Ford JM, et al. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014;38:1501-1509.
174. The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
175. Church DN, Briggs SE, Palles C, et al. DNA polymerase epsilon and delta exonuclease domain mutations in endome-trial cancer. Hum Mol Genet. 2013;22:2820-2828.
176. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst. 2015;107:402.
177. Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol. 2014;134:15-19.
178. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319-1323.
179. Hussein YR, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28: 505-514.
180. van Gool IC, Eggink FA, Freeman-Mills L, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res. 2015;21:3347-3355.
181. Kondratiev S, Sabo E, Yakirevich E, et al. Intratumoral CD8 + T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 2004;10:4450-4456.
182. Cermakova P, Melichar B, Tomsova M, et al. Prognostic significance of CD3 + tumor-infiltrating lymphocytes in patients with endometrial carcinoma. Anticancer Res. 2014;34:5555-5562.
183. de Jong RA, Leffers N, Boezen HM, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114:105-110.
184. Ino K, Yamamoto E, Shibata K, et al. Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res. 2008;14:2310-2317.
185. Workel HH, Komdeur FL, Wouters MC, et al. CD103 defines intraepithelial CD8 + PD1 + tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur J Cancer. 2016;60:1-11.
186. Yamagami W, Susumu N, Tanaka H, et al. Immunofluorescence-detected infiltration of CD4 + FOXP3 + regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer. 2011;21:1628-1634.
187. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
188. Preston CC, Maurer MJ, Oberg AL, et al. The ratios of CD8 + T cells to CD4 + CD25 + FOXP3 + and FOXP3-T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One. 2013;8:e80063.
189. Shah CA, Allison KH, Garcia RL, et al. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109:215-219.
190. Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124:192-198.
191. Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4:e6412.
192. Nielsen JS, Sahota RA, Milne K, et al. CD20 + tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8 + T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18:3281-3292.
193. Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 2016;22:3005-3015.
194. Dieu-Nosjean MC, Goc J, Giraldo NA, et al. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571-580.
195. Santoiemma PP, Reyes C, Wang LP, et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol. 2016;143:120-127.
196. Hermans C, Anz D, Engel J, et al. Analysis of FoxP3 + T-regulatory cells and CD8 + T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers. PLoS One. 2014;9:e111757.
197. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
198. Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67:8900-8905.
199. Stumpf M, Hasenburg A, Riener MO, et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer. 2009;101: 1513-1521.
200. Darb-Esfahani S, Kunze CA, Kulbe H, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016;7:1486-1499.
201. Webb JR, Milne K, Watson P, et al. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20:434-444.
202. Bosmuller HC, Wagner P, Peper JK, et al. Combined Immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer. Int J Gynecol Cancer. 2016;26:671-679.
203. Hagemann AR, Hagemann IS, Cadungog M, et al. Tissue-based immune monitoring II. Cancer Biol Ther. 2014;12: 367-377.
204. Barnett JC, Bean SM, Whitaker RS, et al. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol. 2010;116: 556-562.
205. Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460-3473.
206. Dizon DS. Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection. Gynecol Oncol. 2017;144:241-242.
207. Narod S, Sopik V. Neoadjuvant chemotherapy for advanced-stage ovarian cancer: are the ASCO and SGO recommendations warranted? Gynecol Oncol. 2017;144:238-240.
208. Bohm S, Montfort A, Pearce OM, et al. Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin Cancer Res. 2016;22:3025-3036.
209. Mesnage SJL, Auguste A, Genestie C, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2017;28:651-657.
210. Lo CS, Sanii S, Kroeger DR, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23:925-934.
211. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon: IARC; 2014.
212. Aysal A, Karnezis A, Medhi I, et al. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol. 2012;36:163-172.
213. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
214. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22:393-402.
215. McAlpine JN, Porter H, Kobel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740-750.
216. Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25:625-636.
217. Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587-13598.
218. George J, Alsop K, Etemadmoghadam D, et al. Non-equivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res. 2013;19:3474-3484.
219. Fujiwara M, McGuire VA, Felberg A, et al. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol. 2012;36:1170-1177.
220. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138-1145.
221. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000;6:782-789.
222. Nelson BH. New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Curr Opin Immunol. 2015;33:93-100.
223. Wolf GT, Hudson JL, Peterson KA, et al. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986;95:142-152.
224. De Meulenaere A, Vermassen T, Aspeslagh S, et al. TILs in head and neck cancer: ready for clinical implementation and why (not)? Head Neck Pathol. 2016. [Epub ahead of print].
225. Uppaluri R, Dunn GP, Lewis JS. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immunity. 2008;8:16-26.
226. Wallis SP, Stafford ND, Greenman J. Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers. Head Neck. 2015;37:449-459.
227. Green VL, Michno A, Stafford ND, et al. Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity. Cancer Immunol Immunother. 2013;62:863-873.
228. Economopoulou P, Agelaki S, Perisanidis C, et al. The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 2016;27:1675-1685.
229. Ward MJ, Thirdborough SM, Mellows T, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110:489-500.
230. Oguejiofor K, Hall J, Slater C, et al. Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. Br J Cancer. 2015;113:886-893.
231. Nordfors C, Grun N, Tertipis N, et al. CD8 + and CD4 + tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer. 2013;49:2522-2530.
232. Nasman A, Romanitan M, Nordfors C, et al. Tumor infiltrating CD8 + and Foxp3 + lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One. 2012;7:e38711.
233. Matlung SE, van Kempen PMW, Bovenschen N, et al. Differences in T-cell infiltrates and survival between HPV + and HPV-oropharyngeal squamous cell carcinoma. Future Science. 2016;2:FSO88.
234. Russell SM, Angell TE, Lechner MG, et al. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol. 2013;5:24.
235. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic bio-marker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128-138.
236. Wood O, Woo J, Seumois G, et al. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget. 2016;7:56781-56797.
237. Keck MK, Zuo Z, Khattri A, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015;21: 870-881.
238. Mandal R, Senbabaoglu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1:e89829.
239. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29:167-178.
240. Watanabe Y, Katou F, Ohtani H, et al. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:744-752.
241. Liang YJ, Liu HC, Su YX, et al. Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopatho-logic features and overall survival in tongue squamous cell carcinoma patients. Oral Oncol. 2011;47:566-570.
242. Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. 2016;22:704-713.
243. Wang J, Wang S, Song X, et al. The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma. Onco Targets Ther. 2016;9: 7177-7185.
244. Balermpas P, Michel Y, Wagenblast J, et al. Tumour-infiltrating lymphocytes predict response to definitive chemo-radiotherapy in head and neck cancer. Br J Cancer. 2014; 110:501-509.
245. Balermpas P, Rodel F, Rodel C, et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer. 2016;138:171-181.
246. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956-965.
247. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867.
248. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180-183.
249. Shelley M, Court JB, Kynaston H, et al. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2000;4:CD001986.
250. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezoli-zumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909-1920.
251. Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or meta-static urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18:212-220.
252. Mostofi FK, Sesterhenn I. Plenary lecture: lymphocytic infiltration in relationship to urologic tumors. Natl Cancer Inst Monogr. 1978;49:133-141.
253. Lipponen PK, Eskelinen MJ, Jauhiainen K, et al. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer. 1992;29A:69-75.
254. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothe-lial carcinoma. Proc Natl Acad Sci USA. 2007;104:3967-3972.
255. Winerdal ME, Marits P, Winerdal M, et al. FOXP3 and survival in urinary bladder cancer. BJU Int. 2011;108:1672-1678.
256. Otto W, Denziger S, Wieland WF, et al. First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival. World J Urol. 2012;30:875-877.
257. Krpina K, Babarovic E, Jonjic N. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virch-ows Archiv. 2015;467:443-448.
258. Zhang Q, Hao C, Cheng G, et al. High CD4+ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer. Int J Clin Exp Pathol. 2015;8: 11510-11516.
259. Horn T, Laus J, Seitz AK, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34:181-187.
260. Parodi A, Traverso P, Kalli F, et al. Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence. Oncotarget. 2016;7:6424-6435.
261. Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26:812-877.
262. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506-513.
263. Honda S, Sakamoto Y, Fujime M, et al. Immunohistochem-ical study of tumor-infiltrating lymphocytes before and after intravesical Bacillus Calmette-Guerin treatment for superficial bladder cancer. Int J Urol. 1997;4:68-73.
264. Suriano F, Santini D, Perrone G, et al. Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer. J Exp Clin Cancer Res. 2013;32:87.
265. Ajili F, Kourda N, Dariouche A, et al. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol. 2013;37:56-61.
266. Takayama H, Nishimura K, Tsujimura A, et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical Bacillus Calmette-Guerin instillation. J Urol. 2009;181:1874-1900.
267. Pichler R, Fritz J, Zavadil C, et al. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer. Oncotarget. 2016;7:39916-39930.
268. Baras AS, Drake CG, Liu J-J, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. OncoIm-munology. 2016;5:e1134412.
269. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8 + T cells. Sci Transl Med. 2013;5:ra116.
270. Slovin SF. Immunotherapy for prostate cancer: is prostate an immune responsive tumor? Curr Opin Urol. 2016;26:529-534.
271. Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201:1257-1268.
272. Ebelt K, Babaryka G, Figel AM, et al. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell character-istics in the tumor microenvironment of prostate carcinoma. Prostate. 2008;68:1-10.
273. Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13:6947-6958.
274. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-7405.
275. Sfanos KS, Bruno TC, Maris CH, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. Clin Cancer Res. 2008;14:3254-3261.
276. Sfanos KS, Bruno TC, Meeker AK, et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate. 2009;69:1694-1703.
277. Irani J, Goujon J-M, Ragni E, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology. 1999;54:467-472.
278. Karja V, Aaltomaa S, Lipponen PK, et al. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 2005;25:4435-4438.
279. Zeigler-Johnson C, Morales KH, Lal P, et al. The relationship between obesity, prostate tumor infiltrating lymphocytes and macrophages, and biochemical failure. PLoS One. 2016;11: e0159109.
280. Richardsen E, Uglehaus RD, Due J, et al. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology. 2008;53:30-38.
281. McArdle PA, Canna K, McMillan DC, et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91:541-543.
282. Flammiger A, Bayer F, Cirugeda-Kuhnert A, et al. Intra-tumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012;120:901-908.
283. Ness N, Andersen S, Valkov A, et al. Infiltration of CD8 + lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate. 2014;74:1452-1461.
284. Davidsson S, Ohlson A-L, Andersen S-O, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2013; 26:448-455.
285. Comperat E, Egevad L, Camparo P, et al. Clinical significance of intratumoral CD8 + regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol. 2010;32:39-44.
286. Vesalainen S, Lipponen PK, Talja M, et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994;30: 1797-1803.
287. Nardone V, Botta C, Caraglia M, et al. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. Cancer Biol Ther. 2016;17: 1213-1220.
288. Hussein M-RA, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mod Pathol. 2009;86:108-113.
289. Fujii T, Shimada K, Asai O, et al. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology. 2013;80:119-126.
290. Woo JR, Liss MA, Muldong MT, et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 2014;12:30.
291. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001;98: 14565-14570.
292. Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009;348:9-17.
293. Kantoff P, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
294. McNeel DG, Bander NH, Beer TM, et al. The Society for Immunotherapy of Cancer consensus statement on immuno-therapy for the treatment of prostate carcinoma. J Immun-other Cancer. 2016;4:92.
295. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700-712.
296. Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40-47.
297. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
298. Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7:52810-52817.
299. Rini BI, McDermott DF, Hammers H, et al. Society for Immunotherapy of Cancer consensus statement on immuno-therapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016;4:81.
300. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813.
301. Angevin E, Kremer F, Gaudin C, et al. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer. 1997;72:431-440.
302. Schleypen JS, Baur N, Kammerer R, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res. 2006;12:718-725.
303. Van Den Hove LE, Van Gool SW, Van Poppel H, et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol. 1997;109:501-509.
304. Banner BF, Burnham JA, Bahnson RR, et al. Immunophe-notypic markers in renal cell carcinoma. Mod Pathol. 1990;3:129-134.
305. Kolbeck PC, Kaveggia FF, Johansson SL, et al. The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. Mod Pathol. 1992;5:420-425.
306. Attig S, Hennenlotter J, Pawelec G, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 2009;69:8412-8419.
307. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4 + CD25 + T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13:2075-2081.
308. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007;56:1743-1753.
309. Bromwich EJ, McArdle PA, Canna K, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer. 2003;89:1906-1908.
310. Remark R, Alifano M, Cremer I, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013;19:4079-4091.
311. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8 + T-lymphocytes as a prognostic factor in human renal cell carcinoma. Cancer Res. 2001;61: 5132-5136.
312. Hotta K, Sho M, Fujimoto K, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer. 2011;105:1191-1196.
313. Giraldo NA, Becht E, Pages F, et al. Orchestration and prognostic significance of immune checkpoints in the micro-environment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21:3031-3040.
314. Polimeno M, Napolitano M, Costantini S, et al. Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int. 2013;112:686-696.
315. Kang MJ, Kim KM, Bae JS, et al. Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol. 2013;6:282-289.
316. Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011;107:1500-1506.
317. Li JF, Chu YW, Wang GM, et al. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int. 2009;103:399-405.
318. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757-1761.
319. Abbas M, Steffens S, Bellut M, et al. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma? Med Oncol. 2016;33:59.
320. Guislain A, Gadiot J, Kaiser A, et al. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction human renal cell carcinoma. Cancer Immunol Immunother. 2015;64:1241-1250.
321. Wallin JJ, Bendall JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Comm. 2016;7:12624.
322. Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015;21:1071-1077.
323. Rodriguez-Vida A, Strijbos M, Hutson T. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open. 2016;1:e000013.
324. Bienkowski M, Preusser M. Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: literature review. Curr Opin Neurol. 2015;28:647-658.
325. Domingues P, Gonzalez-Tablas M, Otero A, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016;53:1-15.
326. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17:1064-1075.
327. Rutledge WC, Kong J, Gao J, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res. 2013;19:4951-4960.
328. Han S, Zhang C, Li Q, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014;110:2560-2568.
329. Zhu H-D, Xie Q, Gong Y, et al. Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a systematic literature review. Int J Clin Exp Med. 2013;6:504-515.
330. Fang L, Lowther DE, Meizlish ML, et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol. 2013;15:1479-1490.
331. Bi WL, Wu WW, Santagata S, et al. Checkpoint inhibition in meningiomas. Immunotherapy. 2016;8:721-731.